Article Impact Level: HIGH Data Quality: STRONG Summary of Journal of Internal Medicine https://doi.org/10.1111/joim.70073 Dr. Karl Björkström et al.
Points
- Researchers evaluated immunotherapy outcomes across seven major tumor areas and found that integrating immune checkpoint inhibitors into early stage perioperative care significantly improves event-free survival and pathological response rates.
- Neoadjuvant treatment given while the tumor remains in place allows the immune system to better recognize antigens which often leads to superior results compared to post-surgical adjuvant therapy alone.
- While recurrence free survival is improved by these treatments immune related adverse events occur in up to thirty percent of patients making careful patient selection and toxicity monitoring essential.
- The study identified a critical need for validated biomarkers to help clinicians determine which patients will benefit from early immunotherapy and which may be successfully treated with surgery alone.
- Future oncology research must focus on long term overall survival data and adaptive trial designs to address the substantial healthcare costs and potential for overtreatment in curative intent settings.
Summary
This research evaluated the integration of immune checkpoint inhibitors into the perioperative management of curative-intent oncology, spanning seven major tumor areas including lung, breast, and skin cancers. Data from pivotal trials, such as CheckMate 816 and KEYNOTE-522, indicate that neoadjuvant immunotherapy provides a biological advantage by exposing the immune system to intact tumor antigens. This approach consistently improves event-free survival and pathological complete response rates across various malignancies. Furthermore, emerging evidence suggests that combined neoadjuvant and adjuvant strategies may offer superior outcomes compared to adjuvant treatment alone in specific cohorts.
While adjuvant immunotherapy demonstrates significant recurrence-free survival benefits, overall survival (OS) advantages remain inconsistent across several indications. A critical clinical concern is the risk of overtreatment, particularly in patients potentially cured by surgery alone, compounded by the incidence of immune-related adverse events which occur in up to 30% of patients. Pathological response markers have emerged as robust surrogate endpoints correlating with long-term survival; however, the absence of validated predictive biomarkers across most tumor types remains a significant barrier to precision patient selection and toxicity mitigation.
The findings suggest that while perioperative immunotherapy is rapidly reshaping curative-intent treatment, the field faces substantial challenges regarding healthcare costs and the need for longer-term OS follow-up. Future clinical priorities must include the development of measurable biomarkers to identify high-responder populations and the implementation of adaptive trial designs. Optimal treatment sequencing and safety optimization are essential to ensure that the benefits of early-stage immunotherapy outweigh the risks of chronic toxicity and resource overutilization in diverse healthcare settings.
Link to the article: https://onlinelibrary.wiley.com/doi/10.1111/joim.70073
References
Björkström, K., Matikas, A., Svedman, F. C., Björgvinsson, E., Zupancic, M., Villabona, L., Eriksson, H., Skribek, M., Fernebro, J., Lindskog, M., Frödin, J., Ullén, A., Ekman, S., & Helgadottir, H. (2026). Perioperative immune checkpoint inhibitor therapy across tumors: Insights and shared lessons from a rapidly evolving field. Journal of Internal Medicine, joim.70073. https://doi.org/10.1111/joim.70073
